Vanguard Group Inc. Lowers Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Vanguard trimmed its stake in Medpace by 0.9% to 2,261,848 shares, yet still owns 8.03% of the company valued at about $1.27 billion.
• Medpace beat expectations for the quarter with EPS of $4.28 versus $3.74 and revenue of $706.6M (up 26.5% year-over-year), and set FY2026 guidance of $16.68–$17.50 EPS.
• Analyst and insider activity is mixed: the consensus rating is a "Hold" (four Buys, ten Holds, one Sell) with a $467.08 price target, the company is ~78% institutionally owned, and the president sold 31,707 shares.

Vanguard Group Inc. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,261,848 shares of the company's stock after selling 21,124 shares during the quarter. Vanguard Group Inc. owned 8.03% of Medpace worth $1,270,367,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in MEDP. AQR Capital Management LLC boosted its stake in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after purchasing an additional 211,411 shares during the period. Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Invesco Ltd. boosted its stake in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company's stock valued at $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Qube Research & Technologies Ltd boosted its stake in shares of Medpace by 1,527.8% in the third quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company's stock valued at $38,449,000 after purchasing an additional 70,186 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MEDP. Jefferies Financial Group upgraded shares of Medpace from a "hold" rating to a "buy" rating and set a $560.00 price target for the company in a research note on Friday, February 13th. Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a "market perform" rating for the company in a research note on Wednesday, February 11th. Zacks Research downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 12th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Finally, Weiss Ratings downgraded shares of Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace has an average rating of "Hold" and a consensus price target of $467.08.

Medpace Trading Up 1.2%

Shares of NASDAQ:MEDP opened at $418.66 on Friday. The company has a market capitalization of $11.96 billion, a PE ratio of 26.31, a P/E/G ratio of 2.10 and a beta of 1.39. Medpace Holdings, Inc. has a twelve month low of $284.10 and a twelve month high of $628.92. The firm has a 50 day simple moving average of $468.91 and a 200-day simple moving average of $532.81.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company's revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.50% of the company's stock.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.